Drug
Zastaprazan
Zastaprazan is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_3
2
50%
Ph phase_4
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 32 (50.0%)
Phase 42 (50.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
not_yet_recruitingphase_3
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840
recruitingphase_3
Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction
NCT07467213
recruitingphase_4
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
NCT07471867
recruitingphase_4
Heartburn, Gastroesophageal Reflux Disease
NCT07268820
Clinical Trials (4)
Showing 4 of 4 trials
NCT07730840Phase 3
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07467213Phase 3
Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction
NCT07471867Phase 4
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
NCT07268820Phase 4
Heartburn, Gastroesophageal Reflux Disease
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4